RHEI Pharmaceuticals Receives Approval in China for Its Drs. Hans Schreuder Scar Treatment Product
Posted on: Thursday, 18 December 2008, 08:58 CST
Scar Treatment Product and its Companion Products will Address a Significant Patient and Consumer Need to Restore Normal Skin After Trauma
"We are very pleased with this first approval of a RHEI product in
RHEI Pharmaceuticals will guide the marketing message and marketing support for the product, and is currently negotiating a sales and distribution agreement for hospital and pharmacy detailing with one of the premier distributors of health care products in
About Drs. Hans Schreuder Scar Treatment
Drs. Hans Schreuder Vision for Health Skin Care line contains skin-inherent substances like natural vitamin E and nutritional ingredients from nature itself, such as oatmeal, yeast and hamamelis extracts, soya, rice, natural vitamins and natural lactic acid. These ingredients can solve problems and restore the skin's natural balance. The Scar Treatment product contacts soya extract, which is known to even out skin tone and texture. The cream also contains natural vitamin E, natural lactic acid, and rice and camomile extracts. These nutrients reduce scars while nourishing and moisturizing the skin.
About RHEI Pharmaceuticals
RHEI Pharmaceuticals is a venture backed specialty pharmaceutical company with operations in
SOURCE RHEI Pharmaceuticals, Inc.
Source: PR Newswire
Related Articles
- China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit
- China Biologic Products Appoints Director of Research and Development
- China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
- China Biologic Products Enters into Short-Term Loan Agreement
- China Biologic Products Enters Into International Market With its First Sales Order from India
- China Biologic Products Amends Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
- TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients With Erosive Esophagitis
- China Biopharma Reaches Agreement With a Regional Pharma to Launch New Pharmaceutical Products
- Macugen(R) (Pegaptanib Sodium Injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievement Awards
- Soaring Oil Price Exposes Weakness of China's Oil Product Pricing System
User Comments (0)

RSS Feeds